Previously, based on the screening of a novel series of rhodacyanine-based Hsp70 inhibitors, we identified that compound 1 and compound 6 exhibited high potency to inhibit Hsp70’s chaperone activity and antiproliferative activities against breast cancer cells [31]. This evidence concerns the gene HSPA1A and breast cancer.